Previous efforts to enhance Treg activity in T1D have included low-dose IL-2 in combination with immune-suppressant medications such as rapamycin1 and direct adoptive transfer of CD4 + CD25hi CD127− or CD4 + CD25 + FoxP3+ Tregs2,3. The gene discussed is CD4; the disease is type 1 diabetes mellitus.